CTOs on the Move

LuxCath

www.luxcath.com

 
LuxCath is the leader in using fluorescence and optics to directly view lesions during cardiac ablation procedures. The company`s breakthrough technology offers the potential for dramatic evolution in the way ablation procedures are performed by assessing tissue contact and enabling direct lesion progression monitoring. LuxCath`s patented solution aims to ensure the quality of catheter lesions at the moment they are made. LuxCath enables constant optical tissue contact assessment and provides valuable lesion formation and progression information during each ablation.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.luxcath.com
  • 100 High Street 28th Floor
    Boston, MA USA 02110
  • Phone: 617.419.1800

Executives

Name Title Contact Details
Terry Ransbury
 Chief Technology Officer Profile

Similar Companies

PartsSource

PartsSource is the nation`s only multi-modality, multi-vendor supplier of medical replacement parts.

Respicardia

Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.

Ximedica

Ximedica is a full service ISO 13485 certified and FDA registered product development firm with an exclusive focus on medical products. With more than 25 years of experience developing medical devices, combination products and consumer healthcare products our client base spans the globe and ranges from start-ups to the world's largest OEMs.

St Lawrence Medical Association

St Lawrence Medical Association is a Reading, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chartwell Pennsylvania

Chartwell Pennsylvania is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.